GlobeNewswire Inc | Aug 6, 2020 08:00AM EDT

August 06, 2020

Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD

Platform advancements to beshared include new in vivo RNA editing data

Live webcast scheduled for Tuesday, August 25th at 10:00 a.m. ET

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will hold an Analyst and Investor Research Webcast to discuss its latest PRISM platform advancements and neurology-focused stereopure oligonucleotide pipeline. The webcast is scheduled for Tuesday, August 25th from 10:00-11:30 a.m. ET.

The webcast event will feature presentations from several members ofWave Life Sciencesmanagement, including President and CEO Paul Bolno, MD, MBA, who will present an update on Waves strategy to become a leading genetic medicines company focused on neurology. Chandra Vargeese, PhD, Chief Technology Officer, will present an update on Waves PRISM platform, novel chemistry advancements and new data on Waves ADAR-mediated RNA editing platform capability. Finally, Ken Rhodes, PhD, SVP, Therapeutics Discovery, will present on Waves current neurology pipeline, including its C9orf72 program for amyotrophic lateral sclerosis and frontotemporal dementia, and opportunities to apply PRISM to address additional neurological diseases.

The live webcast will be accessible by visiting the Events section of the Investor Relations page of the Wave Life Sciences corporate website at https://ir.wavelifesciences.com/. The live teleconference can be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 5186597. A replay of the presentation will also be archived and available on the Investor Relations page of Waves website following the event.

About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the companys proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:Kate Rausch 617-949-4827krausch@wavelifesci.com

Media Contact:Alicia Suter617-949-4817asuter@wavelifesci.com